Effective Immediately The U.S. Food and Drug Administration (FDA) has removed tirzepatide, the active ingredient in medications like Mounjaro® and Zepbound®, from the drug shortage list. This change effects compounding pharmacies ability to sell compounded tirzepatide. As an existing customer, you are able to complete your health check in and order up to two more monthly refills of compounded tirzepatide. This is pending no additional regulatory changes that could limit our pharmacy's ability to continue fulfilling these prescriptions. If you recently placed an order that has not yet shipped or if you order a refill, it will be provided by our trusted network pharmacy which compounds the medication with vitamin B12. However, if you prefer not to receive tirzepatide compounded with vitamin B12, please reach out to our customer service team as soon as possible to cancel or switch your order.

After these two months, we encourage you to explore a switch to one of our other GLP-1 treatment options, which include Compounded Semaglutide, Compounded Oral Semaglutide, Ozempic®, and Mounjaro®. Our team is here to assist you in finding the best option for your ongoing weight loss journey to ensure a seamless transition. We understand that this news may be disappointing, as we know so many of you have experienced great success with Compounded Tirzepatide. Rest assured, we remain committed to supporting you on this journey and will soon be launching new treatments as part of our continued commitment to offering effective and innovative solutions for your health and wellness. Please reach out to our customer service team for more information and personalized guidance by email ([email protected]), phone (800-597-0884) or through the patient portal.